{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T23:48:58Z","timestamp":1789948138458,"version":"4.0.1"},"reference-count":15,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2018,8,9]],"date-time":"2018-08-09T00:00:00Z","timestamp":1533772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:p>Nearly all men with prostate cancer who are treated with androgen deprivation therapy develop disease progression. There is considerable evidence to suggest that CXCL 13 released by tumor cells leads to B-cell infiltration into the prostate cells. This B-cell infiltration has been postulated to play a role in development of disease progression following androgen-deprivation therapies. We present a case of a patient who achieved remission of metastatic castrate-resistant prostate cancer after receiving rituximab and bendamustine for the treatment of follicular lymphoma. The findings in this report suggest that further investigation is warranted for utilizing B-cell targeted therapy in delaying progression of castrate-resistant prostate cancer.<\/jats:p>","DOI":"10.1177\/1078155218790338","type":"journal-article","created":{"date-parts":[[2018,8,10]],"date-time":"2018-08-10T01:47:26Z","timestamp":1533865646000},"page":"1509-1511","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["Potential role of rituximab in metastatic castrate-resistant prostate cancer"],"prefix":"10.1177","volume":"25","author":[{"given":"Poorva","family":"Bindal","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, UConn Health, Farmington, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharif AA","family":"Jalil","sequence":"additional","affiliation":[{"name":"UConn School of Pharmacy, Farmington, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M","family":"Holle","sequence":"additional","affiliation":[{"name":"UConn School of Pharmacy, Farmington, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica M","family":"Clement","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, UConn Health, Farmington, CT, USA"},{"name":"UConn School of Medicine, Farmington, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2018,8,9]]},"reference":[{"key":"bibr1-1078155218790338","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.3696"},{"key":"bibr2-1078155218790338","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.4008"},{"key":"bibr3-1078155218790338","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040720"},{"key":"bibr4-1078155218790338","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041318"},{"key":"bibr5-1078155218790338","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014618"},{"key":"bibr6-1078155218790338","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1207506"},{"key":"bibr7-1078155218790338","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2015.00128"},{"key":"bibr8-1078155218790338","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1416498111"},{"key":"bibr9-1078155218790338","doi-asserted-by":"publisher","DOI":"10.1038\/nature08782"},{"key":"bibr10-1078155218790338","doi-asserted-by":"publisher","DOI":"10.1101\/gad.220202.113"},{"key":"bibr11-1078155218790338","doi-asserted-by":"publisher","DOI":"10.1002\/pros.21397"},{"key":"bibr12-1078155218790338","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-12-30"},{"key":"bibr13-1078155218790338","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-014-0063-z"},{"key":"bibr14-1078155218790338","doi-asserted-by":"crossref","unstructured":"Hanna F, Prakash A, Allan E, et\u00a0al. Successful treatment of concomitant metastatic prostate cancer and B-cell non-Hodgkin\u2019s lymphoma with R-EPOCH chemotherapy regimen and antiandrogen therapy.\n                      BMJ Case Rep\n                      . Published Online First: doi:10.1136\/bcr-2017-223637.","DOI":"10.1136\/bcr-2017-223637"},{"key":"bibr15-1078155218790338","unstructured":"Stephen H.\n                      Rituximab neoadjuvant therapy in patients with prostate cancer scheduled to undergo radical prostatectomy\n                      . Bethesda, MD: National Library of Medicine (US), 2000, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01804712 (accessed 8 April 2018)."}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155218790338","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155218790338","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155218790338","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:19:22Z","timestamp":1777688362000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155218790338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,9]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.1177\/1078155218790338"],"URL":"https:\/\/doi.org\/10.1177\/1078155218790338","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,9]]}}}